Grant McArthur

Lorenzo Galli Chair of Melanoma and Skin Cancers

University of Melbourne
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Year:

2026

Year:

2026

Year:

2025

Intracranial metastases (IM) are more common than primary malignant brain tumors, yet have been under-studied, presenting an important unmet clinical need. Many clinical trials excluded patients with IM, limiting our understanding of the intracranial efficacy of emerging treatments, though fortunately this is changing. Nevertheless, IM trials commonly exclude patients with leptomeningeal metastatic disease (LMD), related to their worse prognosis and/or expected lower likelihood of treatment-response. While criteria for assessing treatment-response for patients with confirmed LMD exist, there is a surprising lack of explicit guidelines regarding how LMD should be diagnosed or excluded in broader IM trials. This includes uncertainty regarding when cerebrospinal fluid (CSF) analysis is worthwhile, especially as this can be falsely negative, which is particularly relevant when MRI (magnetic resonance imaging) abnormalities are compelling. This lack of clear guidelines conveys a substantial risk of variability and misdiagnosis, with the potential to compromise trial results. Improved characterization also has the potential to demonstrate differences in treatment-response based on lesion morphology (especially parenchymal versus leptomeningeal). Here, we propose and illustrate new MRI criteria for classifying the range of IM appearances to minimize ambiguity in distinguishing between parenchymal IM and LMD, including recommended next steps. A diagnosis of LMD implies evidence of tumor cells within the CSF, hence we have divided MRI appearances into three groups based on the expected likelihood of this: 1) consistent with LMD and not requiring confirmation by CSF analysis; 2) equivocal, warranting correlation with CSF analysis and/or MRI spine; and 3) low suspicion of LMD, not requiring further testing. Importantly, we do not consider parenchymal metastases that contact a pial surface to be diagnostic of LMD; instead, we classify these within either the equivocal or low suspicion group, depending on morphology. Additionally, we outline potential diagnostic pitfalls and technical considerations for the MRI protocol.

Year:

2025

Year:

2025

Year:

2025

Background Resistance to BRAF and MEK inhibitors (BRAFi/MEKi) in metastatic melanoma frequently results in cross-resistance to immune checkpoint inhibitors (ICI), limiting effective treatment options. However, a subset of BRAFi/MEKi-resistant patients remains responsive to second-line ICI, suggesting heterogeneous underlying resistance mechanisms. This study aimed to explore the tumor immune microenvironment in BRAFi/MEKi-resistant melanoma to uncover factors influencing sensitivity to second-line ICI therapy. Method To investigate mechanisms underlying resistance and responsiveness to second-line ICIs, BRAFi/MEKi-resistant melanoma mouse models were used. Flow cytometry was employed to analyze immune cell populations within the tumor microenvironment, focusing on changes in CD8+T effector cells and other key immune subsets. RNA sequencing was performed to profile transcriptomic changes in resistant tumors, providing insights into the signaling pathways associated with resistance. Clinical samples from BRAFi/MEKi-resistant patients were further evaluated for correlations between immune profiles and key signaling pathways to support findings from the preclinical models. Results Using BRAFi/MEKi-resistant melanoma mouse models, we observed distinct alterations in the tumor-immune microenvironment. Tumors exhibiting resistance showed a significant increase in CD8+T effector cells following BRAFi/MEKi treatment, suggesting an immune-stimulatory response. Mechanistic analysis identified the activation of the EGFR-STAT signaling pathway as a key driver of intrinsic resistance in these models. Notably, these tumors retained sensitivity to second-line ICI therapy, contrasting with NRAS-driven BRAFi/MEKi-resistant tumors, which demonstrated cross-resistance to ICIs. Supporting these findings, clinical samples from BRAFi/MEKi-resistant patients revealed a correlation between elevated EGFR activation and higher immune scores, indicating potential sensitivity to ICI therapy in this subset of patients. Conclusion EGFR overexpression emerges as a potential predictive biomarker for responsiveness to second-line ICIs in BRAFi/MEKi-resistant melanoma. These findings underscore the need for stratified therapeutic approaches and highlight EGFR as a target for improving outcomes in ICI therapy.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (25)

Ilariya Tarasova

University of Melbourne

AUSTRALIA
View details

Emma Link

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Sarah-Jane Dawson

Medical Oncologist and Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

David Seignior

University of Melbourne

AUSTRALIA
View details

Anna Trigos

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

David Ritchie

Head of BMT

-

AUSTRALIA
View details

Claus Garbe

Professor of Dermatology

Eberhard Karls Universität Tübingen

GERMANY
View details

Tamsin Robb

Research Associate

University of Cambridge

UNITED KINGDOM
View details

Penny E Lovat

Prof of Cellular Dermatology & Oncology

Newcastle University

UNITED KINGDOM
View details

Paul Ekert

Group Leader, Translational Tumour Biology

Children's Cancer Institute Australia

AUSTRALIA
View details

Hans Prenen

Antwerp University Hospital

BELGIUM
View details

Ben Tran

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Timothy P. Stinear

University of Melbourne

AUSTRALIA
View details

Charlotta Windahl

Senior Lecturer

University of Auckland

NEW ZEALAND
View details

Jayesh Desai

Associate Director, Clinical Research / Medical Oncology Lead and Trials Lead

-

AUSTRALIA
View details

Luc Thomas

enseignant-chercheur

Centre de Recherche en Cancérologie de Lyon

FRANCE
View details

Fanny Franchini

Senior Research Fellow

University of Melbourne

AUSTRALIA
View details

Benjamin Solomon

Professor

University of Melbourne

AUSTRALIA
View details

Stefanie Thust

Clinical Associate Professor Neuroradiology

University of Nottingham

UNITED KINGDOM
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

Clare Scott

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA
View details

Maarten IJzerman

Full professor

Erasmus University Rotterdam

NETHERLANDS
View details

Jolien Kessels

Vrije Universiteit Brussel

BELGIUM
View details

Ross Hannan

Australian National University

AUSTRALIA
View details

Bart Neyns

Diensthoofd

Vrije Universiteit Brussel

BELGIUM
View details